J Sterz Selected Research

Multiple Myeloma

9/2008	Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
9/2007	Bortezomib inhibits human osteoclastogenesis.
1/2007	Proteasome as an emerging therapeutic target in cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J Sterz Research Topics

Disease

3	Multiple Myeloma 09/2008 - 01/2007
2	Bone Resorption 09/2008 - 09/2007
1	Bone Diseases (Bone Disease) 09/2008
1	Ischemia 01/2007
1	Reperfusion Injury 01/2007
1	Inflammation (Inflammations) 01/2007
1	Stroke (Strokes) 01/2007
1	Neoplasms (Cancer) 01/2007

Drug/Important Bio-Agent (IBA)

2	NF-kappa B (NF-kB)IBA 09/2007 - 01/2007
2	Bortezomib (Velcade)FDA Link 09/2007 - 01/2007
1	CollagenIBA 09/2008
1	Biomarkers (Surrogate Marker)IBA 09/2008
1	AlbuminsIBA 09/2008
1	Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)IBA 09/2007
1	PS1145IBA 09/2007
1	LigandsIBA 09/2007
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 09/2007
1	PS519IBA 01/2007
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2007

Therapy/Procedure

1	Therapeutics 09/2008